The University of Pittsburgh is collaborating with the Food and Drug Administration (FDA) to help people with vision disabilities.
The FDA and the University of Pittsburgh will work together for the next 5 years on scientific collaborations, educational initiatives, and outreach activities designed to address the vision disability.
“It’s really exciting to see this happening. This will put Pitt in a position where we can work with the FDA on the validation of new technological approaches by developing programs and protocols,” said José-Alain Sahel, Pitt’s Eye and Ear Foundation Endowed Chair of the Department of Ophthalmology.
“There is strong expertise at Pitt that is being recognized at an international level. Patients’ voices will nurture our projects and define the successes we all want to deliver.”
“We appreciate this phenomenal opportunity to partner with the University of Pittsburgh. Developing new methods to assess visual impairment and the impact on daily activities is important to help the FDA better characterize the consequences of vision disability, and also helping FDA to reliably assess the benefit of novel therapies and rehabilitation technologies,” said Malvina Eydelman, director of the Office of Ophthalmic, Anesthesia, Respiratory, ENT.
It forms the basis for the development of scientific collaborations, outreach, and educational initiatives between the FDA and the University of Pittsburgh.
